Analysis of changes in drug reimbursement based on the example of the limit groups containing beta-2 adrenergic drugs in Poland in the years 2012-2021
Subject of the study The subject of the study is a price analysis of the limit groups of reimbursed beta-2 adrenergic drugs. Rationalisation of reimbursement expenditure, including generic substitution, is carried out in order to maximise health effects under specific budgetary conditions and to inc...
Main Authors: | Piotr Zbigniew Rykowski, Magdalena Władysiuk, Robert Plisko, Andrzej Stańczak |
---|---|
Format: | Article |
Language: | Polish |
Published: |
Polish Pharmaceutical Society
2022-06-01
|
Series: | Farmacja Polska |
Subjects: | |
Online Access: | https://www.ptfarm.pl/download/?file=File%2FFarmacja+Polska%2F2022%2F4%2F05_SZ_Analiza_zmian_w_refundacji_n.pdf |
Similar Items
-
Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
by: Karolina Badora, et al.
Published: (2017-01-01) -
Reimbursement process of medicinal products in Poland and in the world
by: Aneta Katarzyna Mela
Published: (2020-09-01) -
Drug pricing and reimbursement decision making systems in Mongolia
by: Gereltuya Dorj, et al.
Published: (2017-12-01) -
New reimbursement criteria for lipid-lowering drugs
by: Mario Eandi
Published: (2011-06-01) -
Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market
by: Mihajlo B Jakovljevic
Published: (2014-03-01)